Sergi Ferre

List of Publications by Year
in descending order

285 papers	22,353 citations	5896 81 h-index	11308 136 g-index
287 all docs	287 docs citations	287 times ranked	11492 citing authors

#	Article	IF	Citations
1	G protein-coupled receptor-effector macromolecular membrane assemblies (GEMMAs). , 2022, 231, 107977.		28
2	Heterobivalent Ligand for the Adenosine A_{2A}â€"Dopamine D₂ Receptor Heteromer. Journal of Medicinal Chemistry, 2022, 65, 616-632.	6.4	13
3	Complexes of Ghrelin GHS-R1a, GHS-R1b, and Dopamine D₁Receptors Localized in the Ventral Tegmental Area as Main Mediators of the Dopaminergic Effects of Ghrelin. Journal of Neuroscience, 2022, 42, 940-953.	3.6	10
4	Brain Iron Deficiency Changes the Stoichiometry of Adenosine Receptor Subtypes in Cortico-Striatal Terminals: Implications for Restless Legs Syndrome. Molecules, 2022, 27, 1489.	3.8	11
5	Preferential Gs protein coupling of the galanin Gal1 receptor in the Âµ-opioid-Gal1 receptor heterotetramer. Pharmacological Research, 2022, 182, 106322.	7.1	11
6	Brain-iron deficiency models of restless legs syndrome. Experimental Neurology, 2022, 356, 114158.	4.1	16
7	Decreased striatal adenosine A2A-dopamine D2 receptor heteromerization in schizophrenia. Neuropsychopharmacology, 2021, 46, 665-672.	5.4	24
8	Cellâ€type specific expression and behavioral impact of galanin and GalR1 in the locus coeruleus during opioid withdrawal. Addiction Biology, 2021, 26, e13037.	2.6	4
9	A Randomized, Placeboâ€Controlled Crossover Study with Dipyridamole for Restless Legs Syndrome. Movement Disorders, 2021, 36, 2387-2392.	3.9	22
10	Akathisia and Restless Legs Syndrome. Sleep Medicine Clinics, 2021, 16, 249-267.	2.6	9
11	The Management of Restless Legs Syndrome: An Updated Algorithm. Mayo Clinic Proceedings, 2021, 96, 1921-1937.	3.0	67
12	Heteromerization between Î±2A adrenoceptors and different polymorphic variants of the dopamine D4 receptor determines pharmacological and functional differences. Implications for impulsive-control disorders. Pharmacological Research, 2021, 170, 105745.	7.1	6
13	Consensus Guidelines on Rodent Models of Restless Legs Syndrome. Movement Disorders, 2021, 36, 558-569.	3.9	23
14	Oligomerization of G protein-coupled receptors: Still doubted?. Progress in Molecular Biology and Translational Science, 2020, 169, 297-321.	1.7	20
15	Call for Papers: Adenosine in Inflammation and Cancer. Journal of Caffeine and Adenosine Research, 2020, 10, 41-41.	0.6	0
16	Prefrontal Cortex-Driven Dopamine Signals in the Striatum Show Unique Spatial and Pharmacological Properties. Journal of Neuroscience, 2020, 40, 7510-7522.	3.6	24
17	Call for Papers: Adenosine in the Central Nervous System. Journal of Caffeine and Adenosine Research, 2020, 10, 1-1.	0.6	0
18	Control of glutamate release by complexes of adenosine and cannabinoid receptors. BMC Biology, 2020, 18, 9.	3.8	51

#	Article	IF	Citations
19	Modulation of dopamine D1 receptors via histamine H3 receptors is a novel therapeutic target for Huntington's disease. ELife, 2020, 9, .	6.0	20
20	New Insights into the Neurobiology of Restless Legs Syndrome. Neuroscientist, 2019, 25, 113-125.	3.5	85
21	Adenosine A1-Dopamine D1 Receptor Heteromers Control the Excitability of the Spinal Motoneuron. Molecular Neurobiology, 2019, 56, 797-811.	4.0	36
22	Functional and Neuroprotective Role of Striatal Adenosine A_{2A}Receptor Heterotetramers. Journal of Caffeine and Adenosine Research, 2019, 9, 89-97.	0.6	26
23	Adenosine mechanisms and hypersensitive corticostriatal terminals in restless legs syndrome. Rationale for the use of inhibitors of adenosine transport. Advances in Pharmacology, 2019, 84, 3-19.	2.0	15
24	The Adenosine Hypothesis of Restless Legs Syndrome. Journal of Caffeine and Adenosine Research, 2019, 9, 1-3.	0.6	4
25	Biased G Protein-Independent Signaling of Dopamine D1-D3 Receptor Heteromers in the Nucleus Accumbens. Molecular Neurobiology, 2019, 56, 6756-6769.	4.0	33
26	<i>Call for Papers:</i> Adenosine in Inflammation and Cancer. Journal of Caffeine and Adenosine Research, 2019, 9, 180-180.	0.6	0
27	Astrocytic Mechanisms Involving Kynurenic Acid Control Î”9-Tetrahydrocannabinol-Induced Increases in Glutamate Release in Brain Reward-Processing Areas. Molecular Neurobiology, 2019, 56, 3563-3575.	4.0	20
28	Reinterpreting anomalous competitive binding experiments within G protein-coupled receptor homodimers using a dimer receptor model. Pharmacological Research, 2019, 139, 337-347.	7.1	15
29	Revisiting the Functional Role of Dopamine D4 Receptor Gene Polymorphisms: Heteromerization-Dependent Gain of Function of the D4.7 Receptor Variant. Molecular Neurobiology, 2019, 56, 4778-4785.	4.0	13
30	Opioidâ€“galanin receptor heteromers mediate the dopaminergic effects of opioids. Journal of Clinical Investigation, 2019, 129, 2730-2744.	8.2	41
31	Treatment of restless legs syndrome/Willis-Ekbom disease with the non-selective ENT1/ENT2 inhibitor dipyridamole: testing the adenosine hypothesis. Sleep Medicine, 2018, 45, 94-97.	1.6	44
32	Gs-Âversus Golf-dependent functional selectivity mediated by the dopamine D1 receptor. Nature Communications, 2018, 9, 486.	12.8	38
33	Î±2A- and Î±2C-Adrenoceptors as Potential Targets for Dopamine and Dopamine Receptor Ligands. Molecular Neurobiology, 2018, 55, 8438-8454.	4.0	26
34	The Scope of Adenosine Signaling. Journal of Caffeine and Adenosine Research, 2018, 8, 1-2.	0.6	0
35	Role of placebo effects in pain and neuropsychiatric disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 87, 298-306.	4.8	20
36	Behavioral control by striatal adenosine A_{2A}â€dopamine D₂ receptor heteromers. Genes, Brain and Behavior, 2018, 17, e12432.	2.2	27

#	Article	IF	Citations
37	New Developments on the Adenosine Mechanisms of the Central Effects of Caffeine and Their Implications for Neuropsychiatric Disorders. Journal of Caffeine and Adenosine Research, 2018, 8, 121-130.	0.6	41
38	Design of a True Bivalent Ligand with Picomolar Binding Affinity for a G Protein-Coupled Receptor Homodimer. Journal of Medicinal Chemistry, 2018, 61, 9335-9346.	6.4	34
39	The Role of Adenosine Tone and Adenosine Receptors in Huntington's Disease. Journal of Caffeine and Adenosine Research, 2018, 8, 43-58.	0.6	35
40	Behavioral and cellular dopamine D1 and D3 receptor-mediated synergy: Implications for L-DOPA-induced dyskinesia. Neuropharmacology, 2018, 138, 304-314.	4.1	34
41	What Is the Role of Adenosine Tone and Adenosine Receptors in Huntingtonâ€™s Disease?. , 2018, , 281-308.		2
42	Essential Control of the Function of the Striatopallidal Neuron by Pre-coupled Complexes of Adenosine A2A-Dopamine D2 Receptor Heterotetramers and Adenylyl Cyclase. Frontiers in Pharmacology, 2018, 9, 243.	3.5	73
43	Luciferase complementation based-detection of G-protein-coupled receptor activity. BioTechniques, 2018, 65, 9-14.	1.8	12
44	Cross-communication between Gi and Gs in a G-protein-coupled receptor heterotetramer guided by a receptor C-terminal domain. BMC Biology, 2018, 16, 24.	3.8	70
45	Evidence for functional pre-coupled complexes of receptor heteromers and adenylyl cyclase. Nature Communications, 2018, 9, 1242.	12.8	103
46	Fronto-striatal effective connectivity of working memory in adults with cannabis use disorder. Psychiatry Research - Neuroimaging, 2018, 278, 21-34.	1.8	22
47	Adenosine A2A-dopamine D2 receptor heteromers operate striatal function: impact on Parkinson's disease pharmacotherapeutics. Neural Regeneration Research, 2018, 13, 241.	3.0	6
48	Connectome and molecular pharmacological differences in the dopaminergic system in restless legs syndrome (RLS): plastic changes and neuroadaptations that may contribute to augmentation. Sleep Medicine, 2017, 31, 71-77.	1.6	46
49	Key role of the dopamine D ₄ receptor in the modulation of corticostriatal glutamatergic neurotransmission. Science Advances, 2017, 3, e1601631.	10.3	48
50	Hormones and Neuropeptide Receptor Heteromers in the Ventral Tegmental Area. Targets for the Treatment of Loss of Control of Food Intake and Substance Use Disorders. Current Treatment Options in Psychiatry, 2017, 4, 167-183.	1.9	5
51	Functional Î¼-Opioid-Galanin Receptor Heteromers in the Ventral Tegmental Area. Journal of Neuroscience, 2017, 37, 1176-1186.	3.6	34
52	Development of novel biosensors to study receptor-mediated activation of the G-protein Î± subunits Gs and Golf. Journal of Biological Chemistry, 2017, 292, 19989-19998.	3.4	14
53	Bioluminescence Resonance Energy Transfer Assay to Characterize Giâ€Like G Protein Subtypeâ€Dependent Functional Selectivity. Current Protocols in Neuroscience, 2017, 81, 5.33.1-5.33.13.	2.6	2
54	Allosterism Within GPCR Oligomers: Back to Symmetry. , 2017, , 433-450.		0

#	ARTICLE	IF	CITATIONS
55	In search of alternatives to dopaminergic ligands for the treatment of restless legs syndrome: iron, glutamate, and adenosine. Sleep Medicine, 2017, 31, 86-92.	1.6	34
56	Targeting hypersensitive corticostriatal terminals in restless legs syndrome. Annals of Neurology, 2017, 82, 951-960.	5.3	52
57	Adenosine Control of Striatal Functionâ€"Implications for the Treatment of Apathy in Basal Ganglia Disorders. , 2017, , 231-255.		2
58	Adenosine A1-A2A Receptor Heteromer as a Possible Target for Early-Onset Parkinson's Disease. Frontiers in Neuroscience, 2017, 11, 652.	2.8	10
59	Pivotal Role of Adenosine Neurotransmission in Restless Legs Syndrome. Frontiers in Neuroscience, 2017, 11, 722.	2.8	64
60	Targeting the equilibrative nucleoside transporter ENT1 in Huntington disease. Oncotarget, 2017, 8, 12550-12551.	1.8	4
61	A Novel Class of Dopamine D₄ Receptor Ligands Bearing an Imidazoline Nucleus. ChemMedChem, 2016, 11, 1819-1828.	3.2	7
62	A Significant Role of the Truncated Ghrelin Receptor GHS-R1b in Ghrelin-induced Signaling in Neurons. Journal of Biological Chemistry, 2016, 291, 13048-13062.	3.4	41
63	Adenosine receptors as markers of brain iron deficiency: Implications for Restless Legs Syndrome. Neuropharmacology, 2016, 111, 160-168.	4.1	45
64	Evidence for the heterotetrameric structure of the adenosine A2Aâ€"dopamine D2 receptor complex. Biochemical Society Transactions, 2016, 44, 595-600.	3.4	31
65	Dissecting striatal adenosineâ€cannabinoid receptor interactions. New clues from rats overâ€expressing adenosine A2A receptors. Journal of Neurochemistry, 2016, 136, 897-899.	3.9	3
66	Equilibrative nucleoside transporter ENT1 as a biomarker of Huntington disease. Neurobiology of Disease, 2016, 96, 47-53.	4.4	21
67	Allosteric mechanisms within the adenosine A2Aâ€"dopamine D2 receptor heterotetramer. Neuropharmacology, 2016, 104, 154-160.	4.1	77
68	Local Control of Extracellular Dopamine Levels in the Medial Nucleus Accumbens by a Glutamatergic Projection from the Infralimbic Cortex. Journal of Neuroscience, 2016, 36, 851-859.	3.6	44
69	Mechanisms of the psychostimulant effects of caffeine: implications for substance use disorders. Psychopharmacology, 2016, 233, 1963-1979.	3.1	149
70	Evidence for Noncanonical Neurotransmitter Activation: Norepinephrine as a Dopamine D₂-Like Receptor Agonist. Molecular Pharmacology, 2016, 89, 457-466.	2.3	62
71	The GPCR heterotetramer: challenging classical pharmacology. Trends in Pharmacological Sciences, 2015, 36, 145-152.	8.7	106
72	Allosteric interactions between agonists and antagonists within the adenosine A _{2A} receptor-dopamine D ₂ receptor heterotetramer. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E3609-18.	7.1	135

#	Article	IF	Citations
73	Caffeine increases striatal dopamine D2/D3 receptor availability in the human brain. Translational Psychiatry, 2015, 5, e549-e549.	4.8	106
74	Orexinâ€"Corticotropin-Releasing Factor Receptor Heteromers in the Ventral Tegmental Area as Targets for Cocaine. Journal of Neuroscience, 2015, 35, 6639-6653.	3.6	66
75	Cortico-striatal circuits: Novel therapeutic targets for substance use disorders. Brain Research, 2015, 1628, 186-198.	2.2	53
76	Allosteric Mechanisms in the Adenosine A2A-Dopamine D2 Receptor Heteromer. Current Topics in Neurotoxicity, 2015, , 27-38.	0.4	0
77	Comparison of Caffeine and d-amphetamine in Cocaine-Dependent Subjects: Differential Outcomes on Subjective and Cardiovascular Effects, Reward Learning, and Salivary Paraxanthine. Journal of Addiction Research & Therapy, 2014, 05, 176.	0.2	11
78	Functional Selectivity of Allosteric Interactions within G Proteinâ€"Coupled Receptor Oligomers: The Dopamine D₁-D₃ Receptor Heterotetramer. Molecular Pharmacology, 2014, 86, 417-429.	2.3	114
79	Cocaine Disrupts Histamine H₃Receptor Modulation of Dopamine D₁Receptor Signaling: Ïƒ₁-D₁-H₃Receptor Complexes as Key Targets for Reducing Cocaine's Effects. Journal of Neuroscience, 2014, 34, 3545-3558.	3.6	66
80	Receptor Heteromerization. , 2014, , 91.		0
81	Intracellular Calcium Levels Determine Differential Modulation of Allosteric Interactions within G Protein-Coupled Receptor Heteromers. Chemistry and Biology, 2014, 21, 1546-1556.	6.0	51
82	Personality traits and vulnerability or resilience to substance use disorders. Trends in Cognitive Sciences, 2014, 18, 211-217.	7.8	126
83	G Proteinâ€"Coupled Receptor Oligomerization Revisited: Functional and Pharmacological Perspectives. Pharmacological Reviews, 2014, 66, 413-434.	16.0	497
84	Synthesis and Biological Evaluation of a Novel Series of Heterobivalent Muscarinic Ligands Based on Xanomeline and 1-[3-(4-Butylpiperidin-1-yl)propyl]-1,2,3,4-tetrahydroquinolin-2-one (77-LH-28-1). Journal of Medicinal Chemistry, 2014, 57, 9065-9077.	6.4	24
85	Differential Effects of Presynaptic versus Postsynaptic Adenosine A2A Receptor Blockade on Â9-Tetrahydrocannabinol (THC) Self-Administration in Squirrel Monkeys. Journal of Neuroscience, 2014, 34, 6480-6484.	3.6	35
86	Reducing cannabinoid abuse and preventing relapse by enhancing endogenous brain levels of kynurenic acid. Nature Neuroscience, 2013, 16, 1652-1661.	14.8	85
87	Paraxanthine: Connecting Caffeine to Nitric Oxide Neurotransmission. Journal of Caffeine Research, 2013, 3, 72-78.	0.9	12
88	Caffeine and Substance Use Disorders. Journal of Caffeine Research, 2013, 3, 57-58.	0.9	20
89	Psychostimulant pharmacological profile of paraxanthine, the main metabolite of caffeine in humans. Neuropharmacology, 2013, 67, 476-484.	4.1	64
90	Detection of Receptor Heteromers Involving Dopamine Receptors by the Sequential BRET-FRET Technology. Methods in Molecular Biology, 2013, 964, 95-105.	0.9	10

#	Article	IF	Citations
91	Cocaine Inhibits Dopamine D2 Receptor Signaling via Sigma-1-D2 Receptor Heteromers. PLoS ONE, 2013, 8, e61245.	2.5	112
92	Role of Striatal A2A Receptor Subpopulations in Neurological Disorders. , 2013, , 179-197.		1
93	Circadian-Related Heteromerization of Adrenergic and Dopamine D4 Receptors Modulates Melatonin Synthesis and Release in the Pineal Gland. PLoS Biology, 2012, 10, e1001347.	5.6	132
94	Evidence That Sleep Deprivation Downregulates Dopamine D2R in Ventral Striatum in the Human Brain. Journal of Neuroscience, 2012, 32, 6711-6717.	3.6	203
95	Combined effects of THC and caffeine on working memory in rats. British Journal of Pharmacology, 2012, 165, 2529-2538.	5.4	21
96	Dopamine D4 receptor, but not the ADHD-associated D4.7 variant, forms functional heteromers with the dopamine D2S receptor in the brain. Molecular Psychiatry, 2012, 17, 650-662.	7.9	82
97	Increased Orbitofrontal Brain Activation after Administration of a Selective Adenosine A2A Antagonist in Cocaine Dependent Subjects. Frontiers in Psychiatry, 2012, 3, 44.	2.6	21
98	Dopamineâ€“Galanin Receptor Heteromers Modulate Cholinergic Neurotransmission in the Rat Ventral Hippocampus. Journal of Neuroscience, 2011, 31, 7412-7423.	3.6	31
99	What Do You See as the Main Priorities, Opportunities, and Challenges in Caffeine Research in the Next Five Years?. Journal of Caffeine Research, 2011, 1, 5-12.	0.9	3
100	Pharmacological evidence for different populations of postsynaptic adenosine A2A receptors in the rat striatum. Neuropharmacology, 2011, 61, 967-974.	4.1	41
101	Adenosine A2A Receptors and A2A Receptor Heteromers as Key Players in Striatal Function. Frontiers in Neuroanatomy, 2011, 5, 36.	1.7	44
102	Reinforcing and neurochemical effects of cannabinoid CB1 receptor agonists, but not cocaine, are altered by an adenosine A2A receptor antagonist. Addiction Biology, 2011, 16, 405-415.	2.6	50
103	Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease. , 2011, 132, 280-299.		170
104	Functional changes in postsynaptic adenosine A2A receptors during early stages of a rat model of Huntington disease. Experimental Neurology, 2011, 232, 76-80.	4.1	15
105	Alcohol and Caffeine: The Perfect Storm. Journal of Caffeine Research, 2011, 1, 153-162.	0.9	58
106	Dopamine D1-histamine H3 Receptor Heteromers Provide a Selective Link to MAPK Signaling in GABAergic Neurons of the Direct Striatal Pathway. Journal of Biological Chemistry, 2011, 286, 5846-5854.	3.4	109
107	Striatal Pre- and Postsynaptic Profile of Adenosine A2A Receptor Antagonists. PLoS ONE, 2011, 6, e16088.	2.5	115
108	Adenosineâ€“cannabinoid receptor interactions. Implications for striatal function. British Journal of Pharmacology, 2010, 160, 443-453.	5.4	113

#	Article	IF	Citations
109	Direct involvement of Ïƒ-1 receptors in the dopamine D ₁ receptor-mediated effects of cocaine. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 18676-18681.	7.1	153
110	Interactions between Intracellular Domains as Key Determinants of the Quaternary Structure and Function of Receptor Heteromers. Journal of Biological Chemistry, 2010, 285, 27346-27359.	3.4	102
111	Prime Time for G-Protein-Coupled Receptor Heteromers as Therapeutic Targets for CNS disorders: The Dopamine D1-D3 Receptor Heteromer. CNS and Neurological Disorders - Drug Targets, 2010, 9, 596-600.	1.4	23
112	Platforms for the identification of GPCR targets, and of orthosteric and allosteric modulators. Expert Opinion on Drug Discovery, 2010, 5, 391-403.	5.0	6
113	Oligomerization of G-protein-coupled receptors: A reality. Current Opinion in Pharmacology, 2010, 10, 1-5.	3.5	60
114	Calcium-mediated modulation of the quaternary structure and function of adenosine A2Aâ€“dopamine D2 receptor heteromers. Current Opinion in Pharmacology, 2010, 10, 67-72.	3.5	25
115	Up-regulation of striatal adenosine A2A receptors with iron deficiency in rats. Experimental Neurology, 2010, 224, 292-298.	4.1	27
116	Role of the Central Ascending Neurotransmitter Systems in the Psychostimulant Effects of Caffeine. Journal of Alzheimer's Disease, 2010, 20, S35-S49.	2.6	103
117	G Protein-Coupled Receptor Heteromers as New Targets for Drug Development. Progress in Molecular Biology and Translational Science, 2010, 91, 41-52.	1.7	46
118	The role of orexin and dopamine in sleep alterations from the progressive, neurotoxinâ€induced model of parkinsonism. FASEB Journal, 2010, 24, 300.7.	0.5	1
119	Blocking Striatal Adenosine A2A Receptors: A New Strategy for Basal Ganglia Disorders. , 2010, , 304-341.		4
120	Key Modulatory Role of Presynaptic Adenosine A_{2A}Receptors in Cortical Neurotransmission to the Striatal Direct Pathway. Scientific World Journal, The, 2009, 9, 1321-1344.	2.1	86
121	Interactions between Calmodulin, Adenosine A2A, and Dopamine D2 Receptors. Journal of Biological Chemistry, 2009, 284, 28058-28068.	3.4	65
122	Dopamine D2 and Adenosine A2A Receptors Regulate NMDA-Mediated Excitation in Accumbens Neurons Through A2Aâ€“D2 Receptor Heteromerization. Neuropsychopharmacology, 2009, 34, 972-986.	5.4	174
123	GPCR homomers and heteromers: A better choice as targets for drug development than GPCR monomers?. , 2009, 124, 248-257.		84
124	Effects of chronic caffeine exposure on adenosinergic modulation of the discriminative-stimulus effects of nicotine, methamphetamine, and cocaine in rats. Psychopharmacology, 2009, 203, 355-367.	3.1	31
125	Building a new conceptual framework for receptor heteromers. Nature Chemical Biology, 2009, 5, 131-134.	8.0	349
126	Marked changes in signal transduction upon heteromerization of dopamine D₁ and histamine H₃ receptors. British Journal of Pharmacology, 2009, 157, 64-75.	5.4	138

#	Article	IF	Citations
127	GDNF control of the glutamatergic corticoâ€striatal pathway requires tonic activation of adenosine A_{2A} receptors. Journal of Neurochemistry, 2009, 108, 1208-1219.	3.9	33
128	Metabotropic glutamate type 5, dopamine D₂ and adenosine A_{2a} receptors form higherâ€order oligomers in living cells. Journal of Neurochemistry, 2009, 109, 1497-1507.	3.9	249
129	Diminished iron concentrations increase adenosine A2A receptor levels in mouse striatum and cultured human neuroblastoma cells. Experimental Neurology, 2009, 215, 236-242.	4.1	22
130	Looking for the role of cannabinoid receptor heteromers in striatal function. Neuropharmacology, 2009, 56, 226-234.	4.1	82
131	Light resonance energy transferâ€based methods in the study of G proteinâ€coupled receptor oligomerization. BioEssays, 2008, 30, 82-89.	2.5	37
132	Gâ€proteinâ€coupled receptor heteromers: function and ligand pharmacology. British Journal of Pharmacology, 2008, 153, S90-8.	5.4	60
133	Detection of heteromerization of more than two proteins by sequential BRET-FRET. Nature Methods, 2008, 5, 727-733.	19.0	269
134	An update on the mechanisms of the psychostimulant effects of caffeine. Journal of Neurochemistry, 2008, 105, 1067-1079.	3.9	368
135	Plasma membrane diffusion of g protein-coupled receptor oligomers. Biochimica Et Biophysica Acta - Molecular Cell Research, 2008, 1783, 2262-2268.	4.1	41
136	Novel pharmacological targets based on receptor heteromers. Brain Research Reviews, 2008, 58, 475-482.	9.0	32
137	Interactions between histamine H3 and dopamine D2 receptors and the implications for striatal function. Neuropharmacology, 2008, 55, 190-197.	4.1	157
138	How Calmodulin Interacts with the Adenosine A_{2A} and the Dopamine D₂ Receptors. Journal of Proteome Research, 2008, 7, 3428-3434.	3.7	42
139	Sleep Deprivation Decreases Binding of [¹¹C]Raclopride to Dopamine D₂/D₃Receptors in the Human Brain. Journal of Neuroscience, 2008, 28, 8454-8461.	3.6	168
140	Identification of Dopamine D1â€“D3 Receptor Heteromers. Journal of Biological Chemistry, 2008, 283, 26016-26025.	3.4	216
141	5-HT1B Receptor-Mediated Serotoninergic Modulation of Methylphenidate-Induced Locomotor Activation in Rats. Neuropsychopharmacology, 2008, 33, 619-626.	5.4	43
142	Potential Therapeutic Interest of Adenosine A2A Receptors in Psychiatric Disorders. Current Pharmaceutical Design, 2008, 14, 1512-1524.	1.9	181
143	An Update on Adenosine A2A-Dopamine D2 Receptor Interactions: Implications for the Function of G Protein-Coupled Receptors. Current Pharmaceutical Design, 2008, 14, 1468-1474.	1.9	229
144	Adenosine A1-A2A receptor heteromers: new targets for caffeine in the brain. Frontiers in Bioscience - Landmark, 2008, 13, 2391.	3.0	135

#	Article	IF	Citations
145	Heteromeric Nicotinic Acetylcholineâ€"Dopamine Autoreceptor Complexes Modulate Striatal Dopamine Release. Neuropsychopharmacology, 2007, 32, 35-42.	5.4	63
146	Blocking Striatal Adenosine A2A Receptors: A New Strategy for Basal Ganglia Disorders. Recent Patents on CNS Drug Discovery, 2007, 2, 1-21.	0.9	79
147	Functional relevance of neurotransmitter receptor heteromers in the central nervous system. Trends in Neurosciences, 2007, 30, 440-446.	8.6	136
148	Adenosine receptorâ€"dopamine receptor interactions in the basal ganglia and their relevance for brain function. Physiology and Behavior, 2007, 92, 210-217.	2.1	239
149	Adenosine A2A receptors in ventral striatum, hypothalamus and nociceptive circuitry. Progress in Neurobiology, 2007, 83, 332-347.	5.7	130
150	Adenosine A2A receptors and basal ganglia physiology. Progress in Neurobiology, 2007, 83, 277-292.	5.7	336
151	Working memory deficits in transgenic rats overexpressing human adenosine A2A receptors in the brain. Neurobiology of Learning and Memory, 2007, 87, 42-56.	1.9	115
152	Striatal Adenosine A2A and Cannabinoid CB1 Receptors Form Functional Heteromeric Complexes that Mediate the Motor Effects of Cannabinoids. Neuropsychopharmacology, 2007, 32, 2249-2259.	5.4	229
153	Adenosine Receptor Heteromers and their Integrative Role in Striatal Function. Scientific World Journal, The, 2007, 7, 74-85.	2.1	89
154	Sponsor's Foreword. Scientific World Journal, The, 2007, 7, 1-3.	2.1	0
155	Heteromerization of G-Proteinâ€"Coupled Receptors. Implications for Central Nervous System Function and Dysfunction. Scientific World Journal, The, 2007, 7, 46-47.	2.1	6
156	Basic Concepts in G-Protein-Coupled Receptor Homo- and Heterodimerization. Scientific World Journal, The, 2007, 7, 48-57.	2.1	83
157	Differential glutamate-dependent and glutamate-independent adenosine A1receptor-mediated modulation of dopamine release in different striatal compartments. Journal of Neurochemistry, 2007, 101, 355-363.	3.9	104
158	Neurotransmitter receptor heteromers and their integrative role in â€˜local modulesâ€™: The striatal spine module. Brain Research Reviews, 2007, 55, 55-67.	9.0	112
159	Old and new ways to calculate the affinity of agonists and antagonists interacting with G-protein-coupled monomeric and dimeric receptors: The receptorâ€"dimer cooperativity index. , 2007, 116, 343-354.		70
160	Receptorâ€"receptor interactions involving adenosine A1 or dopamine D1 receptors and accessory proteins. Journal of Neural Transmission, 2007, 114, 93-104.	2.8	69
161	Intramembrane receptorâ€"receptor interactions: a novel principle in molecular medicine. Journal of Neural Transmission, 2007, 114, 49-75.	2.8	113
162	Adenosine A2Aâ€cannabinoid CB1 receptor heteromers. Implications for the rewarding effects of cannabinoids. FASEB Journal, 2007, 21, A410.	0.5	0

#	Article	IF	Citations
163	Allosteric Modulation of Dopamine D2Receptors by Homocysteine. Journal of Proteome Research, 2006, 5, 3077-3083.	3.7	53
164	Heterodimeric adenosine receptors: a device to regulate neurotransmitter release. Cellular and Molecular Life Sciences, 2006, 63, 2427-2431.	5.4	88
165	Stimulation of Adenosine Receptors Selectively Activates Gene Expression in Striatal Enkephalinergic Neurons. Neuropsychopharmacology, 2006, 31, 2173-2179.	5.4	21
166	The Two-State Dimer Receptor Model: A General Model for Receptor Dimers. Molecular Pharmacology, 2006, 69, 1905-1912.	2.3	76
167	Blockade of Adenosine A2A Receptors Prevents Protein Phosphorylation in the Striatum Induced by Cortical Stimulation. Journal of Neuroscience, 2006, 26, 10808-10812.	3.6	25
168	Presynaptic Control of Striatal Glutamatergic Neurotransmission by Adenosine A1-A2A Receptor Heteromers. Journal of Neuroscience, 2006, 26, 2080-2087.	3.6	553
169	Role of Electrostatic Interaction in Receptorâ€“Receptor Heteromerization. Journal of Molecular Neuroscience, 2005, 26, 125-132.	2.3	74
170	How Proteins Come Together in the Plasma Membrane and Function in Macromolecular Assemblies: Focus on Receptor Mosaics. Journal of Molecular Neuroscience, 2005, 26, 133-154.	2.3	28
171	Computer-Assisted Image Analysis of Caveolin-1 Involvement in the Internalization Process of Adenosine A_{2A}â€“Dopamine D₂ Receptor Heterodimers. Journal of Molecular Neuroscience, 2005, 26, 177-184.	2.3	35
172	Receptorâ€“Receptor Interactions, Receptor Mosaics, and Basic Principles of Molecular Network Organization: Possible Implications for Drug Development. Journal of Molecular Neuroscience, 2005, 26, 193-208.	2.3	72
173	Adenosine A_{2A} and Dopamine D₂ Heteromeric Receptor Complexes and Their Function. Journal of Molecular Neuroscience, 2005, 26, 209-220.	2.3	207
174	Partners for Adenosine A₁ Receptors. Journal of Molecular Neuroscience, 2005, 26, 221-232.	2.3	25
175	Heptaspanning Membrane Receptors and Cytoskeletal/Scaffolding Proteins: Focus on Adenosine, Dopamine, and Metabotropic Glutamate Receptor Function. Journal of Molecular Neuroscience, 2005, 26, 277-292.	2.3	25
176	Existence and Theoretical Aspects of Homomeric and Heteromeric Dopamine Receptor Complexes and Their Relevance for Neurological Diseases. NeuroMolecular Medicine, 2005, 7, 061-078.	3.4	21
177	Molecular mechanisms involved in the adenosine A1 and A2A receptor-induced neuronal differentiation in neuroblastoma cells and striatal primary cultures. Journal of Neurochemistry, 2005, 92, 337-348.	3.9	56
178	Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum. Journal of Neurochemistry, 2005, 93, 762-765.	3.9	153
179	Role of central and peripheral adenosine receptors in the cardiovascular responses to intraperitoneal injections of adenosine A₁ and A_{2A} subtype receptor agonists. British Journal of Pharmacology, 2005, 144, 642-650.	5.4	87
180	How receptor mosaics decode transmitter signals. Possible relevance of cooperativity. Trends in Biochemical Sciences, 2005, 30, 188-193.	7.5	56

#	ARTICLE	IF	CITATIONS
181	Dimer-based model for heptaspanning membrane receptors. Trends in Biochemical Sciences, 2005, 30, 360-366.	7.5	60
182	Involvement of adenosine A1 receptors in the discriminative-stimulus effects of caffeine in rats. Psychopharmacology, 2005, 179, 576-586.	3.1	41
183	A detailed behavioral analysis of the acute motor effects of caffeine in the rat: involvement of adenosine A1 and A2A receptors. Psychopharmacology, 2005, 183, 154-162.	3.1	67
184	Studies on homocysteine plasma levels in Alzheimer?s patients. Relevance for neurodegeneration. Journal of Neural Transmission, 2005, 112, 163-169.	2.8	44
185	Energy gradients for the homeostatic control of brain ECF composition and for VT signal migration: introduction of the tide hypothesis. Journal of Neural Transmission, 2005, 112, 45-63.	2.8	37
186	ROLE OF ADENOSINE IN THE CONTROL OF HOMOSYNAPTIC PLASTICITY IN STRIATAL EXCITATORY SYNAPSES. Journal of Integrative Neuroscience, 2005, 04, 445-464.	1.7	45
187	Amazing Stability of the Arginineâˆ'Phosphate Electrostatic Interaction. Journal of Proteome Research, 2005, 4, 1397-1402.	3.7	233
188	OnÂtheÂNestedÂHierarchicalÂOrganizationÂofÂCNS: Basic Characteristics of Neuronal Molecular Networks. Lecture Notes in Computer Science, 2004, , 24-54.	1.3	21
189	Lack of adenosine A1 and dopamine D2 receptor-mediated modulation of the cardiovascular effects of the adenosine A2A receptor agonist CGS 21680. European Journal of Pharmacology, 2004, 484, 269-275.	3.5	13
190	Adenosine receptor-mediated modulation of dopamine release in the nucleus accumbens depends on glutamate neurotransmission and N-methyl-d-aspartate receptor stimulation. Journal of Neurochemistry, 2004, 91, 873-880.	3.9	107
191	On the Molecular Basis of the Receptor Mosaic Hypothesis of the Engram. Cellular and Molecular Neurobiology, 2004, 24, 501-516.	3.3	30
192	Opposite modulatory roles for adenosine A₁and A_{2A}receptors on glutamate and dopamine release in the shell of the nucleus accumbens. Effects of chronic caffeine exposure. Journal of Neurochemistry, 2004, 88, 1151-1158.	3.9	134
193	Combining Mass Spectrometry and Pull-Down Techniques for the Study of Receptor Heteromerization. Direct Epitopeâˆ'Epitope Electrostatic Interactions between Adenosine A2Aand Dopamine D2Receptors. Analytical Chemistry, 2004, 76, 5354-5363.	6.5	195
194	Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinsonâ€™s disease. Brain Research Bulletin, 2004, 64, 155-164.	3.0	32
195	Adenosine A2A-dopamine D2 receptorâ€"receptor heteromers. Targets for neuro-psychiatric disorders. Parkinsonism and Related Disorders, 2004, 10, 265-271.	2.2	132
196	Striatal plasticity at the network level. Focus on adenosine A2A and D2 interactions in models of Parkinson's Disease. Parkinsonism and Related Disorders, 2004, 10, 273-280.	2.2	72
197	Regulation of heptaspanning-membrane-receptor function by dimerization and clustering. Trends in Biochemical Sciences, 2003, 28, 238-243.	7.5	74
198	Homodimerization of adenosine A2A receptors: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. Journal of Neurochemistry, 2003, 88, 726-734.	3.9	139

#	Article	IF	Citations
199	Enabling role of adenosine A1 receptors in adenosine A2A receptor-mediated striatal expression of c-fos. European Journal of Neuroscience, 2003, 18, 296-302.	2.6	45
200	Involvement of Adenosine A1 and A2A Receptors in the Motor Effects of Caffeine after its Acute and Chronic Administration. Neuropsychopharmacology, 2003, 28, 1281-1291.	5.4	177
201	Involvement of Adenosine A1 and A2A Receptors in the Adenosinergic Modulation of the Discriminative-Stimulus Effects of Cocaine and Methamphetamine in Rats. Journal of Pharmacology and Experimental Therapeutics, 2003, 307, 977-986.	2.5	57
202	Adenosine A2A-Dopamine D2 Receptor-Receptor Heteromerization. Journal of Biological Chemistry, 2003, 278, 46741-46749.	3.4	401
203	Molecular Mechanisms and Therapeutical Implications of Intramembrane Receptor/Receptor Interactions among Heptahelical Receptors with Examples from the Striatopallidal GABA Neurons. Pharmacological Reviews, 2003, 55, 509-550.	16.0	306
204	Glutamate mGlu5-Adenosine A2A-Dopamine D2 Receptor Interactions in the Striatum. Implications for Drug Therapy in Neuro-psychiatric Disorders and Drug Abuse. Current Medicinal Chemistry - Central Nervous System Agents, 2003, 3, 1-26.	0.5	18
205	Coaggregation, Cointernalization, and Codesensitization of Adenosine A2A Receptors and Dopamine D2Receptors. Journal of Biological Chemistry, 2002, 277, 18091-18097.	3.4	450
206	Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: Implications for striatal neuronal function. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 11940-11945.	7.1	345
207	Interactions among adenosine deaminase, adenosine A1 receptors and dopamine D1 receptors in stably cotransfected fibroblast cells and neurons. Neuroscience, 2002, 113, 709-719.	2.3	55
208	Metabotropic glutamate mGlu5 receptor-mediated modulation of the ventral striopallidal GABA pathway in rats. Interactions with adenosine A2A and dopamine D2 receptors. Neuroscience Letters, 2002, 324, 154-158.	2.1	124
209	Caffeine Induces Dopamine and Glutamate Release in the Shell of the Nucleus Accumbens. Journal of Neuroscience, 2002, 22, 6321-6324.	3.6	279
210	Local Dopaminergic Modulation of the Motor Activity Induced by N-methyl-D-aspartate Receptor Stimulation in the Ventral Hippocampus. Neuropsychopharmacology, 2002, 26, 737-743.	5.4	17
211	Adenosinergic modulation of the discriminative-stimulus effects of methamphetamine in rats. Psychopharmacology, 2002, 161, 348-355.	3.1	33
212	Heteromerization of Adenosine and Dopamine Receptor Subtypes: Relevance for Neuronal Integration in Normal and Pathological States. Advances in Behavioral Biology, 2002, , 199-204.	0.2	2
213	Adenosine/dopamine interaction: implications for the treatment of Parkinson's disease. Parkinsonism and Related Disorders, 2001, 7, 235-241.	2.2	118
214	Adenosine A2A agonist CGS 21680 decreases the affinity of dopamine D2 receptors for dopamine in human striatum. NeuroReport, 2001, 12, 1831-1834.	1.2	78
215	Activation of Adensine A1 and A2A Receptors Modulates Dopamine D2 Receptor-Induced Responses in Stably Transfected Human Neuroblastoma Cells. Journal of Neurochemistry, 2001, 74, 432-439.	3.9	66
216	Adenosine/dopamine receptor-receptor interactions in the central nervous system. Drug Development Research, 2001, 52, 296-302.	2.9	11

#	Article	IF	Citations
217	The Selective mGlu5 Receptor Agonist CHPG Inhibits Quinpirole-Induced Turning in 6-Hydroxydopamine-Lesioned Rats and Modulates the Binding Characteristics of Dopamine D2 Receptors in the Rat Striatum Interactions with Adenosine A2a Receptors. Neuropsychopharmacology, 2001, 25, 505-513.	5.4	130
218	Electrophysiological and behavioural evidence for an antagonistic modulatory role of adenosine A2Areceptors in dopamine D2receptor regulation in the rat dopamine-denervated striatum. European Journal of Neuroscience, 2000, 12, 4033-4037.	2.6	82
219	Evidence for Adenosine/Dopamine Receptor Interactions Indications for Heteromerization. Neuropsychopharmacology, 2000, 23, S50-S59.	5.4	147
220	Adenosine as a volume transmission signal. A feedback detector of neuronal activation. Progress in Brain Research, 2000, 125, 353-361.	1.4	21
221	Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 8606-8611.	7.1	419
222	Modulation of [35S]GTPÎ³S binding to Chinese hamster ovary cell membranes by D2(short) dopamine receptors. Neuroscience Letters, 2000, 280, 135-138.	2.1	9
223	Stimulation of adenosine A1receptors attenuates dopamine D1receptor-mediated increase of NGFI-A, c-fos and jun-B mRNA levels in the dopamine-denervated striatum and dopamine D1receptor-mediated turning behaviour. European Journal of Neuroscience, 1999, 11, 3884-3892.	2.6	30
224	Reciprocal interactions between adenosine A2A and dopamine D2 receptors in Chinese hamster ovary cells co-transfected with the two receptors. Biochemical Pharmacology, 1999, 58, 1035-1045.	4.4	113
225	Effect of N-methyl-d-aspartate on motor activity and in vivo adenosine striatal outflow in the rat. European Journal of Pharmacology, 1999, 385, 15-19.	3.5	34
226	Adenosine and dopamine receptor antagonist binding in the rat ventral and dorsal striatum: lack of changes after a neonatal bilateral lesion of the ventral hippocampus. Neurochemistry International, 1999, 34, 235-244.	3.8	26
227	Adenosine A2A and group I metabotropic glutamate receptors synergistically modulate the binding characteristics of dopamine D2 receptors in the rat striatum. Neuropharmacology, 1999, 38, 129-140.	4.1	82
228	Serotonergic agonists behave as partial agonists at the dopamine D2 receptor. NeuroReport, 1999, 10, 493-495.	1.2	19
229	Multiple intramembrane receptorâ€"receptor interactions in the regulation of striatal dopamine D2 receptors. NeuroReport, 1999, 10, 2051-2054.	1.2	21
230	Age-related alteration of the adenosine/dopamine balance in the rat striatum. Brain Research, 1998, 795, 297-300.	2.2	29
231	Integrated events in central dopamine transmission as analyzed at multiple levels. Evidence for intramembrane adenosine A2A/dopamine D2 and adenosine A1/dopamine D1 receptor interactions in the basal ganglia1Published on the World Wide Web on 12 January 1998.1. Brain Research Reviews, 1998, 26, 258-273.	9.0	266
232	Adenosine A1 and A2A receptor antagonists stimulate motor activity: evidence for an increased effectiveness in aged rats. Neuroscience Letters, 1998, 251, 201-204.	2.1	62
233	Differential effects of selective adenosine A1 and A2A receptor agonists on dopamine receptor agonist-induced behavioural responses in rats. European Journal of Pharmacology, 1998, 347, 153-158.	3.5	77
234	Adenosine A1 Receptor-mediated Modulation of Dopamine D1 Receptors in Stably Cotransfected Fibroblast Cells. Journal of Biological Chemistry, 1998, 273, 4718-4724.	3.4	98

#	Article	IF	Citations
235	Adenosineâ€“dopamine receptorâ€“receptor interactions as an integrative mechanism in the basal ganglia. Trends in Neurosciences, 1997, 20, 482-487.	8.6	758
236	Prolonged treatment with haloperidol and clozapine in the rat: differential effects on spontaneous and theophylline-induced motor activity. Neuroscience Letters, 1997, 232, 21-24.	2.1	3
237	Adenosine A2A Agonists: A Potential New Type of Atypical Antipsychotic. Neuropsychopharmacology, 1997, 17, 82-91.	5.4	149
238	Different Effects of Dopamine Antagonists on Spontaneous and NMDA-Induced Motor Activity in Mice. Pharmacology Biochemistry and Behavior, 1997, 56, 549-553.	2.9	23
239	GABA-dopamine receptor-receptor interactions in neostriatal membranes of the rat. Neurochemical Research, 1997, 22, 1051-1054.	3.3	18
240	Adenosine-dopamine interactions in the ventral striatum. Psychopharmacology, 1997, 133, 107-120.	3.1	222
241	Adenosine A1 receptor-dopamine D1 receptor interaction in the rat limbic system: modulation of dopamine D1 receptor antagonist binding sites. Neuroscience Letters, 1996, 208, 109-112.	2.1	67
242	Reserpine potentiates NMDA-induced c-fos mRNA expression in the mouse brain. Neuroscience Letters, 1996, 212, 147-150.	2.1	5
243	Stimulation of adenosine A1 receptors prevents the EEG arousal due to dopamine D1 receptor activation in rabbits. European Journal of Pharmacology, 1996, 305, 123-126.	3.5	20
244	Adenosine A2A receptors modulate the binding characteristics of dopamine D2 receptors in stably cotransfected fibroblast cells. European Journal of Pharmacology, 1996, 316, 325-331.	3.5	91
245	Motor depressant effects of systemically administered polyamines in mice: involvement of central NMDA receptors. European Journal of Pharmacology, 1996, 318, 231-238.	3.5	10
246	Adenosine A1 receptor blockade selectively potentiates the motor effects induced by dopamine D1 receptor stimulation in rodents. Neuroscience Letters, 1996, 218, 209-213.	2.1	69
247	Neuropharmacology of the adenosine A2A receptors. Drug Development Research, 1996, 39, 450-460.	2.9	21
248	Dopamine D1Receptor-mediated Facilitation of GABAergic Neurotransmission in the Rat Strioentopeduncular Pathway and its Modulation by Adenosine A1Receptor-mediated Mechanisms. European Journal of Neuroscience, 1996, 8, 1545-1553.	2.6	134
249	NMDA-Induced Motor Activation in Rodents. , 1996, , 85-94.		0
250	Effects of the systemic administration of kainic acid and NMDA on exploratory activity in rats. Pharmacology Biochemistry and Behavior, 1995, 51, 205-210.	2.9	14
251	A brief appraisal on some aspects of the receptor-receptor interaction. Neurochemistry International, 1995, 27, 139-146.	3.8	22
252	Dopamine-independent and adenosine-dependent mechanisms involved in the effects of N-methyl-d-aspartate on motor activity in mice. European Journal of Pharmacology, 1995, 275, 171-177.	3.5	26

#	Article	IF	Citations
253	Clozapine decreases serotonin extracellular levels in the nucleus accumbens by a dopamine receptor-independent mechanism. Neuroscience Letters, 1995, 187, 61-64.	2.1	38
254	Evidence for the Existence of Antagonistic Intramembrane Adenosine A2a/dopamine D2 Receptor Interactions in the Basal Ganglia: Analysis from the Network to the Molecular Level. , 1995, , 499-507.		5
255	Chronic haloperidol treatment leads to an increase in the intramembrane interaction between adenosine A2 and dopamine D2 receptors in the neostriatum. Psychopharmacology, 1994, 116, 279-284.	3.1	32
256	Unilateral neonatal intracerebroventricular 6-hydroxydopamine administration in rats: II. Effects on extracellular monoamine, acetylcholine and adenosine levels monitored with in vivo microdialysis. Psychopharmacology, 1994, 116, 451-456.	3.1	26
257	Motor activation in short- and long-term reserpinized mice: role of , dopamine D1 and dopamine D2 receptors. European Journal of Pharmacology, 1994, 255, 203-213.	3.5	32
258	Antagonistic interaction between adenosine A2A receptors and dopamine D2 receptors in the ventral striopallidal system. Implications for the treatment of schizophrenia. Neuroscience, 1994, 63, 765-773.	2.3	170
259	PEC-60 increases dopamine but not GABA release in the dorsolateral neostriatum of the halothane anaesthetized rat. An in vivo microdialysis study. Neuroscience Letters, 1994, 177, 53-57.	2.1	13
260	Postsynaptic antagonistic interaction between adenosine A1, and dopamine D1 receptors. NeuroReport, 1994, 6, 73-76.	1.2	133
261	Antagonistic A2a/D2receptor interactions in the striatum as a basis for adenosine/dopamine interactions in the central nervous system. Drug Development Research, 1993, 28, 374-380.	2.9	50
262	Opposing actions of an adenosine A2 receptor agonist and a GTP analogue on the regulation of dopamine D2 receptors in rat neostriatal membranes. European Journal of Pharmacology, 1993, 244, 311-315.	2.6	53
263	Receptor-receptor interactions as an integrative mechanism in nerve cells. Molecular Neurobiology, 1993, 7, 293-334.	4.0	124
264	Noradrenergic modulation of midbrain dopamine cell firing elicited by stimulation of the locus coeruleus in the rat. Journal of Neural Transmission, 1993, 93, 11-25.	2.8	268
265	Dopamine D₂ Receptorâ€Mediated Regulation of Serotonin Extracellular Concentration in the Dorsal Raphe Nucleus of Freely Moving Rats. Journal of Neurochemistry, 1993, 61, 772-775.	3.9	76
266	Adenosine-dopamine interactions in the brain. Neuroscience, 1992, 51, 501-512.	2.3	350
267	Dopamine denervation leads to an increase in the intramembrane interaction between adenosine A2 and dopamine D2 receptors in the neostriatum. Brain Research, 1992, 594, 124-130.	2.2	103
268	Stimulation of adenosine A2 receptors induces catalepsy. Neuroscience Letters, 1991, 130, 162-164.	2.1	108
269	Postsynaptic dopamine/adenosine interaction: I. Adenosine analogues inhibit dopamine D2-mediated behaviour in short-term reserpinized mice. European Journal of Pharmacology, 1991, 192, 25-30.	3.5	94
270	Postsynaptic dopamine/adenosine interaction: II. Postsynaptic dopamine agonism and adenosine antagonism of methylxanthines in short-term reserpinized mice. European Journal of Pharmacology, 1991, 192, 31-37.	3.5	95

#	Article	IF	Citations
271	High-performance liquid chromatographic separation of caffeine, theophylline, theobromine and paraxanthine in rat brain and serum. Biomedical Applications, 1991, 570, 185-190.	1.7	20
272	A trypsin inhibitor-like peptide PEC-60 reduces the affinity of dopamine D2 agonist binding sites in rat neostriatal membranes. European Journal of Pharmacology, 1991, 207, 365-366.	2.6	6
273	Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 7238-7241.	7.1	499
274	T-maze performance in rats following chronic neuroleptic treatment. Pharmacology Biochemistry and Behavior, 1990, 35, 481-484.	2.9	3
275	Is experimental catalepsy properly measured?. Pharmacology Biochemistry and Behavior, 1990, 35, 753-757.	2.9	75
276	Effect of unilateral nucleus basalis lesion on cortical and striatal acetylcholine and dopamine release monitored in vivo with microdialysis. Neuroscience Letters, 1990, 110, 172-179.	2.1	47
277	Paraxanthine displaces the binding of [3H]SCH 23390 from rat striatal membranes. European Journal of Pharmacology, 1990, 179, 295-299.	3.5	23
278	Rotational behaviour induced by theophylline in 6-OHDA nigrostriatal denervated rats is dependent on the supersensitivity of striatal dopaminergic receptors. Pharmacology Biochemistry and Behavior, 1989, 33, 609-613.	2.9	17
279	Methylxanthines cause a decrease of prolactin plasma levels in healthy non-pregnant women. Human Psychopharmacology, 1989, 4, 33-39.	1.5	2
280	Relationship between rotational behaviour induced by apomorphine and caffeine in rats with unilateral lesion of the nigrostriatal pathway. Neuropharmacology, 1989, 28, 407-409.	4.1	45
281	BHT-920 and LY-171555 (quinpirole) have similar affinities for striatal D-2 dopamine receptors, and similar affinities for striatal D-1 dopamine receptors. European Journal of Pharmacology, 1989, 166, 303-305.	3.5	4
282	Conditioning of rotational behavior after the administration of a single dose of apomorphine in rats with unilateral denervation of the dopaminergic nigrostriatal pathway: Relevance to drug addiction. Pharmacology Biochemistry and Behavior, 1988, 31, 605-609.	2.9	22
283	Comparison between apomorphine and amphetamine-induced rotational behaviour in rats with a unilateral nigrostriatal pathway lesion. Neuropharmacology, 1988, 27, 657-659.	4.1	16
284	Theophylline reverses haloperidol-induced catalepsy in the rat possible relevance to the pharmacological treatment of psychosis. Biological Psychiatry, 1988, 24, 642-648.	1.3	26
285	L-dopa causes an acute, partial and reversible reversal of denervation-induced supersensitivity of striatal dopaminergic receptors. Psychopharmacology, 1987, 91, 254-6.	3.1	3